# Intratumoral Administration of L19IL2/L19TNF

> **NCT02076633** · PHASE2 · COMPLETED · sponsor: **Philogen S.p.A.** · enrollment: 21 (actual)

## Conditions studied

- Malignant Melanoma, Skin

## Interventions

- **DRUG:** L19IL2+L19TNF

## Key facts

- **NCT ID:** NCT02076633
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2015-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02076633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02076633, "Intratumoral Administration of L19IL2/L19TNF". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02076633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*